Results 71 to 80 of about 7,837 (201)

The contemporary role of blood products and components used in trauma resuscitation

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2010
Introduction There is renewed interest in blood product use for resuscitation stimulated by recent military experience and growing recognition of the limitations of large-volume crystalloid resuscitation.
Dries David J
doaj   +1 more source

Bronchoscopic Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage-induced Acute Respiratory Failure in MPO-ANCA Vasculitis: A Case Report. [PDF]

J Crit Care Med (Targu Mures), 2022
Smesseim I, Schaepman-Ruys T, Duitman JW, Vegting Y, Raasveld J, Hilhorst M, Vlaar A, van Es J, Bonta P.   +8 more
europepmc   +1 more source

Recombinant factor VIIa for life-threatening post-partum haemorrhage [PDF]

, 2005
Alexander J. Butwick, Edward T. Riley
openalex   +1 more source

Fatal scenario following dental extraction in middle‐aged man with history of acquired hemophilia: Employment of surgical tracheostomy and use of FFP and cryoprecipitate to gain patent airway

Clinical Case Reports
Key Clinical Message Acquired hemophilia A can upshot in a life‐threatening hemorrhage and airway obstruction. Airway bleeding is a weighty emergency in hemophilia care, necessitating the immediate start of effective hemostatic therapy (porcine factor ...
Sunil Bhatta MD, Sukriti Pandit MBBS, Sabin Nepal MD, Pratik Chaudhary MD   +3 more
doaj   +1 more source

Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. [PDF]

Int J Stroke, 2022
Naidech AM, Grotta J, Elm J, Janis S, Dowlatshahi D, Toyoda K, Steiner T, Mayer SA, Khanolkar P, Denlinger J, Audebert HJ, Molina C, Khatri P, Sprigg N, Vagal A, Broderick JP.   +15 more
europepmc   +1 more source

Use of Recombinant Factor VIIa in Gastrointestinal Bleeding in Children with Malignancies: A Case Series

Proceedings of Singapore Healthcare, 2010
Recombinant factor VIIa (rFVIIa) may be useful in management of severe bleeding in paediatric oncology patients. We described our experience and outcomes in a form of a case series.
Jan Hau Lee MBBS, MRCPCH, Heng Joo Ng MRCP (UK), FAMS, Mei Yoke Chan MMed (Paeds), MRCP (Paeds)   +2 more
doaj   +1 more source

Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. [PDF]

J Manag Care Spec Pharm, 2022
Alexander WA, Jensen I, Hathway J, Srivastava K, Cyr P, Sidonio RF, Batt K.   +6 more
europepmc   +1 more source

Use of recombinant factor VIIa in inherited platelet disorders [PDF]

, 2004
Mohamed Kaleelrahman, Adrian Minford, L. A. Parapia   +2 more
openalex   +1 more source

Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India

Heliyon
Introduction: Severe Haemophilia A patients with inhibitors are currently being treated with bypassing agents like activated prothrombin complex concentrates (aPCC) and recombinant factor VIIa.
Yuvaraj Krishnamoorthy, Dhanajayan Govindan, Narasimhapriyan Kannan, Marie Gilbert Majella, Vishnu Shankar Hariharan, Vivek Valliappan   +5 more
doaj   +1 more source

Successful use of one dose of recombinant factor VIIa to control severe bleeding after emergency aortic arch replacement in deep hypothermic circulatory arrest [PDF]

, 2004
Christoph Wiesenack, Matthias Arlt, Andreas Liebold, Franz X. Schmid   +3 more
openalex   +1 more source